JP2019533426A - アミロイドベータに対する抗体 - Google Patents

アミロイドベータに対する抗体 Download PDF

Info

Publication number
JP2019533426A
JP2019533426A JP2019501965A JP2019501965A JP2019533426A JP 2019533426 A JP2019533426 A JP 2019533426A JP 2019501965 A JP2019501965 A JP 2019501965A JP 2019501965 A JP2019501965 A JP 2019501965A JP 2019533426 A JP2019533426 A JP 2019533426A
Authority
JP
Japan
Prior art keywords
seq
antibody
cdr
sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2019501965A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019533426A5 (cg-RX-API-DMAC7.html
Inventor
アール． キャッシュマン，ニール
アール． キャッシュマン，ニール
エス． プロトキン，スティーブン
エス． プロトキン，スティーブン
カプラン，ヨハンネ
マックスウェル シルバーマン，ジュディス
マックスウェル シルバーマン，ジュディス
ギブス，エブリマ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Promis Neurosciences Inc
Original Assignee
Promis Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CA2016/051303 external-priority patent/WO2017079833A1/en
Application filed by Promis Neurosciences Inc filed Critical Promis Neurosciences Inc
Publication of JP2019533426A publication Critical patent/JP2019533426A/ja
Publication of JP2019533426A5 publication Critical patent/JP2019533426A5/ja
Priority to JP2022130540A priority Critical patent/JP7357834B2/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1716—Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Wood Science & Technology (AREA)
JP2019501965A 2016-07-18 2017-07-18 アミロイドベータに対する抗体 Ceased JP2019533426A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022130540A JP7357834B2 (ja) 2016-07-18 2022-08-18 アミロイドベータに対する抗体

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662363566P 2016-07-18 2016-07-18
US62/363,566 2016-07-18
PCT/CA2016/051303 WO2017079833A1 (en) 2015-11-09 2016-11-09 Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto
CAPCT/CA2016/051303 2016-11-09
US201762443766P 2017-01-08 2017-01-08
US62/443,766 2017-01-08
US201762507633P 2017-05-17 2017-05-17
US201762507587P 2017-05-17 2017-05-17
US62/507,587 2017-05-17
US62/507,633 2017-05-17
PCT/CA2017/050866 WO2018014126A1 (en) 2016-07-18 2017-07-18 Antibodies to amyloid beta

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022130540A Division JP7357834B2 (ja) 2016-07-18 2022-08-18 アミロイドベータに対する抗体

Publications (2)

Publication Number Publication Date
JP2019533426A true JP2019533426A (ja) 2019-11-21
JP2019533426A5 JP2019533426A5 (cg-RX-API-DMAC7.html) 2020-08-27

Family

ID=60991830

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019501965A Ceased JP2019533426A (ja) 2016-07-18 2017-07-18 アミロイドベータに対する抗体
JP2022130540A Active JP7357834B2 (ja) 2016-07-18 2022-08-18 アミロイドベータに対する抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022130540A Active JP7357834B2 (ja) 2016-07-18 2022-08-18 アミロイドベータに対する抗体

Country Status (8)

Country Link
US (2) US12071472B2 (cg-RX-API-DMAC7.html)
EP (1) EP3484919A4 (cg-RX-API-DMAC7.html)
JP (2) JP2019533426A (cg-RX-API-DMAC7.html)
KR (1) KR102550991B1 (cg-RX-API-DMAC7.html)
CN (2) CN116333108A (cg-RX-API-DMAC7.html)
AU (1) AU2017299858B2 (cg-RX-API-DMAC7.html)
CA (1) CA3031135A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018014126A1 (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020533955A (ja) * 2017-07-18 2020-11-26 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータに対する抗体
US11905318B2 (en) 2015-11-09 2024-02-20 The University Of British Columbia Cyclic compound/peptide comprising an A-beta13-16 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-beta13-16 peptide
US12071472B2 (en) 2016-07-18 2024-08-27 The University Of British Columbia Methods of reducing toxicity induced by Amyloid beta (A-beta) oligomers using antibodies specific to A-beta oligomers
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3004498A1 (en) 2015-11-09 2017-05-18 Neil R. Cashman Amyloid beta epitopes and antibodies thereto
EP3374379A4 (en) 2015-11-09 2019-05-15 The University Of British Columbia N-TERMINAL EPITOPES IN AMYLOID BETA AND CONFORMATION-SELECTIVE ANTIBODIES
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
AU2019304384B2 (en) 2018-07-17 2025-11-06 Jiangsu Hengrui Medicine Co., Ltd. Anti-Abeta antibody, antigen-binding fragment thereof and application thereof
EP3861015A4 (en) * 2018-10-07 2022-11-23 The University of British Columbia CONFORMATION SPECIFIC EPITOPES IN ALPHA-SYNUCLEIN, ANTIBODIES DIRECTED AGAINST AND METHODS THEREOF
GB201912008D0 (en) * 2019-08-21 2019-10-02 Cambridge Entpr Ltd Antibody
KR102397684B1 (ko) * 2019-12-09 2022-05-13 (주)옵토레인 항체의 항원 결합 부위에 결합하는 펩티드 및 이를 이용한 분석 방법
KR102504175B1 (ko) * 2020-06-17 2023-02-28 (주)옵토레인 항체의 항원 결합 부위에 결합하는 펩타이드, 이를 이용한 약물 복합체, 바이오센서 및 분석 방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011504360A (ja) * 2007-11-16 2011-02-10 ザ ロックフェラー ユニバーシティー ベータ−アミロイドタンパク質のプロトフィブリルの形態に特異的な抗体
JP2012524023A (ja) * 2009-04-17 2012-10-11 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
JP2013500941A (ja) * 2009-08-06 2013-01-10 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
JP2013537424A (ja) * 2010-08-14 2013-10-03 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
GB8911525D0 (en) 1989-05-19 1989-07-05 Allied Colloids Ltd Polymeric composition
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5562909A (en) 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
AU7642494A (en) 1993-08-31 1995-03-22 Gliatech Inc. Inhibition of beta amyloid binding to glycosaminoglycans for treatment of alzheimer's disease
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US20030072774A1 (en) 1994-06-10 2003-04-17 Diane M. Gajewczyk Proteinaceous adjuvants
US6019982A (en) 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
FR2726764B1 (fr) 1994-11-14 1997-01-31 Pasteur Merieux Serums Vacc Adjuvant pour composition vaccinale
WO1996028471A1 (en) 1995-03-14 1996-09-19 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
AU1072897A (en) 1995-12-12 1997-07-03 Karolinska Innovations Ab Peptide binding the klvff-sequence of amyloid beta
US5735814A (en) 1996-04-30 1998-04-07 Medtronic, Inc. Techniques of treating neurodegenerative disorders by brain infusion
US6071493A (en) 1996-09-20 2000-06-06 Baylor College Of Medicine Method of screening for an agent that inhibits mononuclear phagocyte-plaque component complex formation
US6043283A (en) 1996-09-20 2000-03-28 Baylor College Of Medicine Tyramine compounds and their neuronal effects
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7012061B1 (en) 1998-10-19 2006-03-14 New York University Method for increasing the permeability of the blood brain barrier
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
MXPA02005576A (es) 1999-11-29 2002-12-13 Neurochem Inc Vacuna para la prevencion y tratamiento de la enfermedad de alzheimer y otras enfermedades relacionadas con amiloides.
US20020094335A1 (en) 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
SI1481992T1 (sl) 2000-02-24 2017-01-31 Washington University St. Louis Humanizirana protitelesa, ki vežejo amiloidni peptid beta
AU2007234495A1 (en) 2000-09-08 2007-12-06 Board Of Regents, The University Of Texas System Biopanning and rapid analysis of selective interactive ligands (BRASIL)
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
JP2005501220A (ja) 2000-12-19 2005-01-13 パラチン テクノロジーズ インク． ペプチドおよび蛋白質の標的特異的折りたたみ部位の識別
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1523499A2 (en) 2002-07-24 2005-04-20 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
US9535076B2 (en) 2002-09-12 2017-01-03 The Regents Of The University Of California Methods and compositions for eliciting an amyloid-selective immune response
WO2004029629A1 (en) 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
EP1581203A1 (en) 2002-12-24 2005-10-05 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
US7575747B2 (en) 2003-02-10 2009-08-18 Applied Molecular Evolution Aβ binding molecules
CN101245105A (zh) * 2003-03-28 2008-08-20 森托科尔公司 抗淀粉状蛋白抗体、组合物、方法和用途
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
JP2007527865A (ja) 2003-09-12 2007-10-04 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 種々の配列を有するタンパク質から形成されたアミロイドに共通の高分子量凝集中間体に特異的なモノクローナル抗体
CN1562050A (zh) 2004-03-24 2005-01-12 中国海洋大学 褐藻酸寡糖在抗痴呆、抗糖尿病中的应用
US20050267029A1 (en) 2004-04-02 2005-12-01 Ancsin John B Compounds which modulate amyloidogenesis and methods for their identification and use
EP1838348B1 (en) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanized amyloid beta antibodies for use in improving cognition
ES2396555T3 (es) 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
EP1676859A1 (en) 2004-12-30 2006-07-05 Pevion Biotech Ltd. Immunogenic compositions of cyclic peptides derived from the beta-amyloid peptide
ES2259270B1 (es) 2005-03-09 2007-11-01 Consejo Superior De Investigaciones Cientificas Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal.
CA2609980C (en) 2005-05-27 2015-10-13 Queen's University At Kingston Treatment of protein folding disorders
WO2007059000A2 (en) 2005-11-10 2007-05-24 Roskamp Research, Llc Modulation of angiogenesis by a-beta peptide fragments
ATE517923T1 (de) 2005-12-12 2011-08-15 Hoffmann La Roche Antikörper gegen amyloid beta mit glykosilierung in der variablen region
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
DK2074145T5 (en) 2006-10-02 2017-10-16 Ac Immune Sa HUMANIZED ANTIBODY AGAINST AMYLOID BETA
EP2842967B1 (en) 2007-01-18 2016-11-30 Eli Lilly and Company Pegylated amyloid beta fab
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
BRPI0812484A2 (pt) 2007-06-12 2018-06-05 Ac Immune Sa anticorpo monoclonal, regiões variáveis de cadeia leve e de cadeia pesada, cdr isolada, polinucleotídeo, composição terapêutica, métodos para tratar doenças e distúrbios, para produzir um anticorpo, para tratar ou aliviar os efeitos de doenças e distúrbios, para reduzir a carga de placas no cérebro de um indivíduo, para reduzir a quantidade de placas no cérebro de um indivíduo, para diminuir a quantidade total de abeta solúvel no cérebro de um indivíduo, para reter ou aumentar a capacidade de memória cognitiva em um indivíduo, de diagnose de ou para diagnosticar uma predisposição para uma doença associada com amilóide ou condição em um paciente, para determinar a extensão de carga de placa amiloidogênica em um tecido de um indivíduo, para monitorar doença residual mínima em um indivíduo e para prever responsividade de um indivíduo, linhagem de células, kit de teste, epítopo abeta
US20090155249A1 (en) 2007-06-12 2009-06-18 Ac Immune S.A. Humanized antibody igg1
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
EP2650308A3 (en) 2007-10-05 2014-11-12 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
NZ585110A (en) 2007-10-05 2012-09-28 Genentech Inc Method and compositions for diagnosis and treatment of amyloidosis
US20090246191A1 (en) 2007-10-11 2009-10-01 University Of Tennessee Research Foundation Preparation of Purified Covalently Cross-linked Abeta Oligomers and Uses Thereof
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
KR20100097651A (ko) 2007-10-29 2010-09-03 인썸 베타-아밀로이드 펩티드에 특이적인 신규 항체 및 진단제 또는 진단약으로서의 그 용도
DK2237803T3 (en) 2007-12-28 2015-10-05 Prothena Biosciences Ltd Treatment and prophylaxis of amyloidosis
WO2009143489A2 (en) 2008-05-22 2009-11-26 Archer Pharmaceuticals, Inc. Modulation of angiogenesis by a-beta peptide fragments
AT506819B1 (de) 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
JP2011522842A (ja) 2008-06-12 2011-08-04 アフィリス・アクチェンゲゼルシャフト パーキンソン病に関連する症状の治療のための化合物
AT509611B1 (de) 2008-06-12 2012-04-15 Affiris Forschungs-Und Entwicklungs Gmbh Vakzin
RU2546234C2 (ru) 2008-07-01 2015-04-10 Де Стат Дер Недерланден, Верт.Дор Де Министер Ван Ввс Вакцина против интермедиата с амилоидным сворачиванием
US9801865B2 (en) 2008-09-24 2017-10-31 The United States Of America As Represented By The Department Of Veteran Affairs Materials and methods for diagnosis, prevention and/or treatment of stress disorders and conditions associated with abeta peptide aggregation
EP2342220B1 (en) 2008-10-06 2021-05-12 The University Of British Columbia Methods and systems for predicting misfolded protein epitopes
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2010128139A1 (en) 2009-05-08 2010-11-11 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Biomarkers and methods for diagnosing alzheimer's disease and/ or mild cognitive impairment
JP5692073B2 (ja) * 2009-08-07 2015-04-01 協和発酵キリン株式会社 抗アミロイドβオリゴマーヒト化抗体
SG10201405802UA (en) 2009-09-18 2014-11-27 Probiodrug Ag Novel assay for the detection of amyloid beta peptides
ES2661925T3 (es) 2010-02-26 2018-04-04 Bioarctic Ab Anticuerpos de unión a las protofibrillas y su uso en métodos terapéuticos diagnósticos para la enfermedad de Parkinson, la demencia con cuerpos de Lewy y otras alfa-sinucleinopatías
EP2542571B1 (en) 2010-03-03 2016-05-25 The University of British Columbia Oligomer-specific amyloid beta epitope and antibodies
US20110256064A1 (en) 2010-04-16 2011-10-20 Ac Immune, S.A. Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-like Proteins
BR112012026249B1 (pt) 2010-04-16 2021-08-17 Ac Immune Sa Composto, formulação radiofarmacêutica, composição farmacêutica, uso do composto, mistura, métodos de coletar dados para o diagnóstico de uma doença ou condição associadas com amiloide, de determinar a extensão de carga amiloidogênica de placas em um tecido e/ou um fluido corporal, de coletar dados para determinar uma predisposição a uma doença ou condição associadas com amiloide em um paciente, de coletar dados para monitorar a doença residual mínima em um paciente seguindo o tratamento com um anticorpo ou uma composição de vacina, de coletar dados para predizer capacidade de reação de um paciente sendo tratado com um anticorpo ou uma composição de vacina, e, kit de teste
CA2817973C (en) 2010-10-15 2019-06-25 The Board Of Regents Of The University Of Texas System Antibodies that bind amyloid oligomers
US20120321694A1 (en) 2010-10-27 2012-12-20 Daniel Larocque Compositions and uses
FR2966827B1 (fr) 2010-10-27 2014-08-22 Kimonella Ventures Ltd Compose peptidique utile pour l'inhibition de la formation de plaques amyloides
WO2012104824A1 (en) 2011-02-04 2012-08-09 Ecole polytechnique fédérale de Lausanne (EPFL) Therapeutic antibodies targeting app-c99
EP2511296A1 (en) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
CN104093454A (zh) 2011-11-10 2014-10-08 坎格尼美国股份有限公司 治疗阿耳茨海默氏病的组合物和方法
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
JP2015527369A (ja) 2012-08-21 2015-09-17 インスティテュート フォー モレキュラー メディシン， インコーポレイテッド アミロイド、タウおよびα−シヌクレインの沈着に関連する疾患に関する組成物および方法
EP2787347A1 (en) 2013-04-03 2014-10-08 Affiris AG Method for detecting Aß-specific antibodies in a biological sample
EP3030580A4 (en) 2013-08-05 2017-04-05 St. Vincent's Institute Of Medical Research An antibody therapy for amyloid beta disease
BR112016004242A8 (pt) * 2013-08-28 2018-06-12 Stemcentrx Inc Métodos para conjugação sítio-específica de anticorpos e composições
CA2938129A1 (en) 2014-02-03 2015-08-06 Cangene Corporation Humanized beta-amyloid binding molecules and uses thereof
WO2016138525A1 (en) * 2015-02-27 2016-09-01 University Of Washington Polypeptide assemblies and methods for the production thereof
US20170021020A1 (en) 2015-07-23 2017-01-26 The Board Of Trustees Of The Leland Stanford Junior University Monoclonal antibody and vaccine targeting filamentous bacteriophage
RS59688B1 (sr) 2015-08-11 2020-01-31 Novartis Ag 5-bromo-2,6-di-(1h-pirazol-1-il)pirimidin-4-amin za upotrebu pri lečenju raka
EP3374379A4 (en) 2015-11-09 2019-05-15 The University Of British Columbia N-TERMINAL EPITOPES IN AMYLOID BETA AND CONFORMATION-SELECTIVE ANTIBODIES
US11756650B2 (en) * 2015-11-09 2023-09-12 The University Of British Columbia Systems and methods for predicting misfolded protein epitopes by collective coordinate biasing
US20180326027A1 (en) 2015-11-09 2018-11-15 The University Of British Columbia Epitopes in amyloid beta and conformationally-selective antibodies thereto
WO2017079832A1 (en) 2015-11-09 2017-05-18 The University Of British Columbia C-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
CA3004498A1 (en) * 2015-11-09 2017-05-18 Neil R. Cashman Amyloid beta epitopes and antibodies thereto
JP7448174B2 (ja) 2015-11-09 2024-03-12 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータ中間領域エピトープおよびそれに対する立体配座選択的抗体
KR102550991B1 (ko) * 2016-07-18 2023-07-04 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타에 대한 항체
US20180125920A1 (en) * 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011504360A (ja) * 2007-11-16 2011-02-10 ザ ロックフェラー ユニバーシティー ベータ−アミロイドタンパク質のプロトフィブリルの形態に特異的な抗体
JP2012524023A (ja) * 2009-04-17 2012-10-11 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
JP2013500941A (ja) * 2009-08-06 2013-01-10 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
JP2013537424A (ja) * 2010-08-14 2013-10-03 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11905318B2 (en) 2015-11-09 2024-02-20 The University Of British Columbia Cyclic compound/peptide comprising an A-beta13-16 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-beta13-16 peptide
US12071472B2 (en) 2016-07-18 2024-08-27 The University Of British Columbia Methods of reducing toxicity induced by Amyloid beta (A-beta) oligomers using antibodies specific to A-beta oligomers
JP2020533955A (ja) * 2017-07-18 2020-11-26 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータに対する抗体
JP7330164B2 (ja) 2017-07-18 2023-08-21 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータに対する抗体
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)

Also Published As

Publication number Publication date
AU2017299858A1 (en) 2019-02-07
KR20190028495A (ko) 2019-03-18
CN116333108A (zh) 2023-06-27
WO2018014126A1 (en) 2018-01-25
CA3031135A1 (en) 2018-01-25
EP3484919A4 (en) 2020-03-04
US20200172602A1 (en) 2020-06-04
AU2017299858B2 (en) 2024-07-25
EP3484919A1 (en) 2019-05-22
JP2022172166A (ja) 2022-11-15
US20250051428A1 (en) 2025-02-13
JP7357834B2 (ja) 2023-10-10
CN109476729A (zh) 2019-03-15
KR102550991B1 (ko) 2023-07-04
US12071472B2 (en) 2024-08-27

Similar Documents

Publication Publication Date Title
JP7357834B2 (ja) アミロイドベータに対する抗体
US11779629B2 (en) Compositions comprising cyclic peptides derived from an A-beta peptide
AU2022201737B2 (en) Epitopes in Amyloid beta mid-region and conformationally-selective antibodies thereto
US11970522B2 (en) Cyclic compound/peptide comprising an A-beta15-18 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-BETA15-18 peptide
JP2019505165A (ja) アミロイドベータのｃ末端エピトープおよびそれに対する立体配座選択的抗体
US12286469B2 (en) Humanized antibodies binding to amyloid-beta (A-beta)
JP2023086132A (ja) アミロイドベータに対する抗体
US20250289877A1 (en) Antibodies to Amyloid Beta
HK40017344B (en) Antibodies to amyloid beta
HK40017344A (en) Antibodies to amyloid beta

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200717

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200717

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210907

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220311

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220719

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20221129